Interfaith Care Center | |
811 Third Street, Carlton, Minnesota 55718 | |
(218) 384-4258 | |
Name | Interfaith Care Center |
---|---|
Location | 811 Third Street, Carlton, Minnesota |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 96 |
Occupancy Rate | 67.92% |
Medicare ID (CCN) | 245024 |
Legal Business Name | Inter-faith Care Center |
Ownership Type | Non Profit - Corporation |
NPI Number | 1134125644 |
Organization Name | INTER-FAITH CARE CENTER |
Address | 811 3rd St, Carlton, MN 55718 |
Phone Number | 218-384-4258 |
News Archive
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.
Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.
Most dermatologists would agree that premature skin aging can result from sun over-exposure, poor antioxidant intake, and excess free-radical production. Additionally, regarding hair health, about 20 million U.S. women experience premature hair-loss and hair-thinning. Natrol, Inc., a premier marketer, manufacturer, and distributor of nationally branded nutritional products, now offers two new beauty nutraceuticals that help provide anti-aging skin and hair support for women - one dietary supplement helps optimize skin radiance via antioxidant protection for the skin, and another helps maximize follicular growth for hair.
"The rise of non-communicable diseases (NCDs)" is "a growing but under-addressed challenge in both the developed and developing world," Jean-Luc Butel, executive vice president and group president for Medtronic's international operations, writes in a Muskegon Chronicle opinion piece.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.
Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.
Most dermatologists would agree that premature skin aging can result from sun over-exposure, poor antioxidant intake, and excess free-radical production. Additionally, regarding hair health, about 20 million U.S. women experience premature hair-loss and hair-thinning. Natrol, Inc., a premier marketer, manufacturer, and distributor of nationally branded nutritional products, now offers two new beauty nutraceuticals that help provide anti-aging skin and hair support for women - one dietary supplement helps optimize skin radiance via antioxidant protection for the skin, and another helps maximize follicular growth for hair.
"The rise of non-communicable diseases (NCDs)" is "a growing but under-addressed challenge in both the developed and developing world," Jean-Luc Butel, executive vice president and group president for Medtronic's international operations, writes in a Muskegon Chronicle opinion piece.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $23091 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.32 | 14.46 |
Percentage of long-stay residents who lose too much weight | 4.64 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 68.47 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 8.2 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.17 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.2 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 1.5 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 12.16 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 93.57 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 13.6 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.71 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 1.93 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |